ARTVNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Artiva Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$5.89+0.04 (+0.68%)
Close on Oct 19, 2026
- Market cap
- $232.14M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
83.2%
41M of 49M shares
Institutional holders
72
39 new, 7 sold out
Net institutional buying
24M
In Q2 2026
Insider trades, 12 months
22 buys · 14 sales
Net bought $107.39M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| GC Corp | 5,999,703 | 12.30% | 13D (active) amendment | May 11, 2026 |
| Viking Global Opportunities Parent GP LLC | 2,604,166 | 5.40% | 13G (passive) | May 11, 2026 |
| Peter Kolchinsky | 18,415,956 | 37.90% | 13D (active) amendment | Jul 22, 2026 |
| Rajeev Shah | 17,811,623 | 36.60% | 13D (active) amendment | Jun 11, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ARTV | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 17,955,642 | 36.73% | $174.17M | +8,102,340 | 1.51% |
| Viking Global Investors LP | 2,604,166 | 5.33% | $25.26M | New | 0.07% |
| Blackstone Inc. | 2,403,437 | 4.92% | $23.31M | New | 0.07% |
| 5AM Venture Management, LLC | 2,353,304 | 4.81% | $22.83M | – | 7.93% |
| VR Adviser, LLC | 2,043,596 | 4.18% | $19.82M | +434,027 | 0.60% |
| Franklin Resources Inc | 1,997,223 | 4.09% | $19.37M | +1,476,896 | 0.00% |
| Caligan Partners LP | 1,736,111 | 3.55% | $16.84M | New | 0.79% |
| Vanguard Capital Management LLC | 981,815 | 2.01% | $9.52M | +774,129 | 0.00% |
| Samsara BioCapital, LLC | 954,861 | 1.95% | $9.26M | New | 0.76% |
| Blue Owl Capital Holdings LP | 874,542 | 1.79% | $8.48M | New | 1.28% |
| Propel Bio Management, LLC | 696,436 | 1.42% | $6.76M | +550,067 | 3.54% |
| BlackRock, Inc. | 694,726 | 1.42% | $6.74M | +481,338 | 0.00% |
| Citadel Advisors LLC | 609,376 | 1.25% | $5.91M | +593,506 | 0.00% |
| Nantahala Capital Management, LLC | 600,000 | 1.23% | $5.82M | New | 0.10% |
| Silverarc Capital Management, LLC | 525,000 | 1.07% | $5.09M | New | 0.53% |
| Geode Capital Management, LLC | 353,845 | 0.72% | $3.43M | +252,150 | 0.00% |
| Boothbay Fund Management, LLC | 314,375 | 0.64% | $3.05M | New | 0.04% |
| Revelation Capital Management, LLC | 299,311 | 0.61% | $2.90M | – | 2.65% |
| Alyeska Investment Group, L.P. | 273,615 | 0.56% | $2.65M | +173,615 | 0.01% |
| Acuta Capital Partners, LLC | 260,416 | 0.53% | $2.53M | New | 1.76% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 72 | 41M | 83.2% | 39 / 25 | 2 / 7 | 25M | 1M |
| Q1 2026 | 40 | 17M | 34.4% | 12 / 3 | 12 / 5 | 1M | 0M |
| Q4 2025 | 34 | 17M | 34.7% | 6 / 4 | 15 / 12 | 1M | 2M |
| Q3 2025 | 40 | 18M | 37.1% | 6 / 8 | 16 / 14 | 1M | 1M |
| Q2 2025 | 48 | 19M | 37.9% | 12 / 9 | 16 / 17 | 1M | 3M |
| Q1 2025 | 53 | 21M | 42.8% | 4 / 22 | 12 / 7 | 1M | 1M |
| Q4 2024 | 57 | 21M | 43.3% | 9 / 18 | 6 / 1 | 0M | 0M |
| Q3 2024 | 49 | 21M | 42.4% | 49 / 0 | 0 / 0 | 21M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ARTV | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 699,899 | 1.43% | $6.79M | 0.00% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 542,371 | 1.11% | $5.48M | 0.47% | Jul 31, 2026 |
| Franklin Small Cap Growth Fund | 456,468 | 0.93% | $4.61M | 0.19% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 269,149 | 0.55% | $2.61M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 140,593 | 0.29% | $1.36M | 0.00% | Jun 30, 2026 |
| Simplify Propel Opportunities ETF | 101,355 | 0.21% | $983.14K | 1.27% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 51,557 | 0.11% | $520.73K | 0.00% | Jul 31, 2026 |
| Ultra-Small Company Fund | 50,000 | 0.10% | $485.00K | 0.49% | Jun 30, 2026 |
| Ultra-Small Company Market Fund | 35,000 | 0.07% | $339.50K | 0.23% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 30,895 | 0.06% | $245.00K | 0.00% | May 31, 2026 |
| U.S. Micro Cap Portfolio | 27,426 | 0.06% | $277.00K | 0.00% | Jul 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 23,015 | 0.05% | $223.25K | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 20,825 | 0.04% | $202.00K | 0.00% | Jun 30, 2026 |
| Nationwide Bailard Small Cap Value Fund | 20,700 | 0.04% | $209.07K | 0.16% | Jul 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 16,258 | 0.03% | $128.93K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Fred Aslan | Chief Executive Officer, Director | 1,604,765 | 3.28% | Sep 15, 2026 |
| Jennifer Bush | COO, CLO, Compliance Officer | 374,529 | 0.77% | Sep 11, 2026 |
| Christopher Horan | Chief Tech Operations Officer | 323,084 | 0.66% | Sep 11, 2026 |
| Gines Diego Miralles | President & Head of R&D | 122,500 | 0.25% | Sep 11, 2026 |
| Subhashis Banerjee | Chief Medical Officer | 170,947 | 0.35% | Sep 11, 2026 |
| Heather Raymon | SVP, Research and Development | 148,228 | 0.30% | May 19, 2026 |
| Thad Allen Huston | Chief Financial Officer | 220,000 | 0.45% | Mar 10, 2026 |
| Neha Krishnamohan | Chief Financial Officer | 99,356 | 0.20% | Nov 17, 2025 |
| Thorsten Graef | Chief Medical Officer | 80,000 | 0.16% | Feb 28, 2025 |
| Capital Healthcare Fund LP RA | Director, 10% owner | 17,329,570 | 35.45% | Sep 14, 2026 |
| Alison Moore | Director | – | – | Sep 14, 2026 |
| Elaine K. Sorg | Director | – | – | Sep 14, 2026 |
| Brian Daniels | Director | – | – | Sep 14, 2026 |
| Rajeev M. Shah | Director, 10% owner | 16,817,573 | 34.40% | Sep 14, 2026 |
| RA Capital Nexus Fund III, L.P. | Director | 17,283,802 | 35.35% | Sep 14, 2026 |
| Peter Kolchinsky | Director, 10% owner | 17,242,483 | 35.27% | Sep 14, 2026 |
| RA Capital Nexus Fund, L.P. | Director | 16,817,543 | 34.40% | Sep 14, 2026 |
| Ra Capital Management, L.P. | Director, 10% owner | 16,795,919 | 34.35% | Sep 14, 2026 |
| Daniel G. Baker | Director | – | – | Sep 14, 2026 |
| Laura Stoppel | Director | – | – | Sep 14, 2026 |
| Elizabeth L. Hougen | Director | – | – | Sep 14, 2026 |
| Corp. GC | 10% owner | 5,999,703 | 12.27% | May 28, 2026 |
| Cell Corp GC | 10% owner | 1,541,371 | 3.15% | May 28, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Fred Aslan Chief Executive Officer, Director | Sep 15, 2026 | Award | +110,000 | – | – | 1,604,765 |
| Fred Aslan Chief Executive Officer, Director | Sep 10, 2026 | Award | +45,000 | – | – | 1,494,765 |
| Gines Diego Miralles President & Head of R&D | Sep 9, 2026 | Award | +45,000 | – | – | 122,500 |
| Subhashis Banerjee Chief Medical Officer | Sep 9, 2026 | Award | +30,000 | – | – | 170,947 |
| Christopher Horan Chief Tech Operations Officer | Sep 9, 2026 | Award | +40,000 | – | – | 323,084 |
| Jennifer Bush COO, CLO, Compliance Officer | Sep 9, 2026 | Award | +45,000 | – | – | 374,529 |
| Fred Aslan Chief Executive Officer, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −23,429 | $10.92 | $255.84K | 1,449,765 |
| Jennifer Bush COO, CLO, Compliance Officer | Sep 3, 2026 | Sale | −8,391 | $11.16 | $93.64K | 329,529 |
| Subhashis Banerjee Chief Medical Officer | Sep 3, 2026 | Sale | −1,100 | $11.16 | $12.28K | 140,947 |
| Christopher Horan Chief Tech Operations Officer | Sep 3, 2026 | Sale | −10,366 | $11.16 | $115.68K | 283,084 |
| Fred Aslan Chief Executive Officer, Director | Sep 3, 2026 | Sale | −61,888 | $11.16 | $690.67K | 1,473,194 |
| Subhashis Banerjee Chief Medical Officer | Aug 27, 2026 | Sale(10b5-1 plan) | −8,222 | $12.01 | $98.75K | 142,047 |
| Subhashis Banerjee Chief Medical Officer | Aug 27, 2026 | Option exercise | +5,306 | $1.92 | $10.19K | 150,269 |
| Subhashis Banerjee Chief Medical Officer | Aug 18, 2026 | Option exercise | +429 | $1.92 | $824 | 145,392 |
| Subhashis Banerjee Chief Medical Officer | Aug 18, 2026 | Sale(10b5-1 plan) | −429 | $12.00 | $5.15K | 144,963 |
| Capital Healthcare Fund LP RA Director, 10% owner | Jul 31, 2026 | Buy | +24,944 | $9.93 | $247.69K | 17,329,570 |
| Capital Healthcare Fund LP RA Director, 10% owner | Jul 29, 2026 | Buy | +20,824 | $9.99 | $208.03K | 17,304,626 |
| RA Capital Nexus Fund III, L.P. Director | Jul 24, 2026 | Buy | +41,319 | $9.99 | $412.78K | 17,283,802 |
| Peter Kolchinsky Director, 10% owner | Jul 23, 2026 | Buy | +59,880 | $9.96 | $596.40K | 17,242,483 |
| Peter Kolchinsky Director, 10% owner | Jul 22, 2026 | Buy | +84,124 | $9.93 | $835.35K | 17,182,603 |
| Peter Kolchinsky Director, 10% owner | Jul 21, 2026 | Buy | +120,582 | $9.55 | $1.15M | 17,098,479 |
| Capital Healthcare Fund LP RA Director, 10% owner | Jul 17, 2026 | Buy | +7,882 | $8.95 | $70.54K | 16,977,927 |
| Capital Healthcare Fund LP RA Director, 10% owner | Jul 16, 2026 | Buy | +152,472 | $8.93 | $1.36M | 16,970,045 |
| RA Capital Nexus Fund, L.P. Director | Jul 13, 2026 | Buy | +6,522 | $8.94 | $58.31K | 16,817,543 |
| Rajeev M. Shah Director, 10% owner | Jul 13, 2026 | Buy | +6,552 | $8.94 | $58.57K | 16,817,573 |
| Rajeev M. Shah Director, 10% owner | Jul 10, 2026 | Buy | +15,102 | $8.97 | $135.46K | 16,811,021 |
| Ra Capital Management, L.P. Director, 10% owner | Jun 26, 2026 | Buy | +1,876 | $8.98 | $16.85K | 16,795,919 |
| Ra Capital Management, L.P. Director, 10% owner | Jun 25, 2026 | Buy | +31,000 | $8.88 | $275.28K | 16,794,043 |
| Peter Kolchinsky Director, 10% owner | Jun 16, 2026 | Buy | +124,893 | $8.89 | $1.11M | 16,763,043 |
| Peter Kolchinsky Director, 10% owner | Jun 15, 2026 | Buy | +15,414 | $8.99 | $138.57K | 16,638,150 |
| Peter Kolchinsky Director, 10% owner | Jun 12, 2026 | Buy | +391,019 | $8.57 | $3.35M | 16,622,736 |
| RA Capital Nexus Fund, L.P. Director | Jun 11, 2026 | Buy | +548,580 | $7.91 | $4.34M | 16,231,717 |
| RA Capital Nexus Fund, L.P. Director | Jun 10, 2026 | Buy | +103 | $7.00 | $721 | 15,683,137 |
| RA Capital Nexus Fund, L.P. Director | Jun 9, 2026 | Buy | +479,039 | $6.91 | $3.31M | 15,683,034 |
| Fred Aslan Chief Executive Officer, Director | May 19, 2026 | Sale | −27,116 | $9.01 | $244.32K | 1,535,082 |
| Christopher Horan Chief Tech Operations Officer | May 19, 2026 | Sale | −7,002 | $9.01 | $63.09K | 293,450 |
| Jennifer Bush COO, CLO, Compliance Officer | May 19, 2026 | Sale | −8,790 | $9.01 | $79.20K | 337,920 |
| Heather Raymon SVP, Research and Development | May 19, 2026 | Sale | −3,095 | $9.01 | $27.89K | 148,228 |
| Subhashis Banerjee Chief Medical Officer | May 19, 2026 | Sale | −7,037 | $9.01 | $63.40K | 144,963 |
| Gines Diego Miralles President & Head of R&D | May 18, 2026 | Award | +77,500 | – | – | 77,500 |
| Corp. GC 10% owner | May 11, 2026 | Buy | +347,222 | $11.52 | $4.00M | 1,607,734 |
| Corp. GC 10% owner | May 11, 2026 | Buy | +1,085,069 | $11.52 | $12.50M | 4,391,969 |
| RA Capital Nexus Fund III, L.P. Director | May 11, 2026 | Buy | +6,510,416 | $11.52 | $75.00M | 15,203,995 |
| Thad Allen Huston Chief Financial Officer | Mar 10, 2026 | Award | +220,000 | – | – | 220,000 |
| Subhashis Banerjee Chief Medical Officer | Feb 15, 2026 | Award | +102,000 | – | – | 152,000 |
| Jennifer Bush COO, CLO, Secy, Compliance Off | Feb 15, 2026 | Tax withholding | −3,515 | $4.00 | $14.06K | 346,710 |
| Jennifer Bush COO, CLO, Secy, Compliance Off | Feb 15, 2026 | Award | +117,300 | – | – | 350,225 |
| Christopher Horan Chief Tech Operations Officer | Feb 15, 2026 | Award | +117,300 | – | – | 302,639 |
| Christopher Horan Chief Tech Operations Officer | Feb 15, 2026 | Tax withholding | −2,187 | $4.00 | $8.75K | 300,452 |
| Fred Aslan President and CEO, Director | Feb 15, 2026 | Award | +366,850 | – | – | 1,576,798 |
| Fred Aslan President and CEO, Director | Feb 15, 2026 | Tax withholding | −14,600 | $4.00 | $58.40K | 1,562,198 |
| Heather Raymon SVP, Research and Development | Feb 15, 2026 | Tax withholding | −1,521 | $4.00 | $6.08K | 151,323 |
| Heather Raymon SVP, Research and Development | Feb 15, 2026 | Award | +46,000 | – | – | 152,844 |
| Fred Aslan President and CEO, Director | Dec 15, 2025 | Sale(10b5-1 plan) | −3,187 | $6.00 | $19.12K | 1,209,948 |
| Fred Aslan President and CEO, Director | Dec 12, 2025 | Award | +869,136 | – | – | 1,213,135 |
| Jennifer Bush COO, CLO, Secy, Compliance Off | Dec 12, 2025 | Award | +84,877 | – | – | 232,925 |
| Heather Raymon SVP, Research and Development | Dec 12, 2025 | Award | +67,253 | – | – | 106,844 |
| Christopher Horan Chief Tech Operations Officer | Dec 12, 2025 | Award | +107,156 | – | – | 185,339 |
| Fred Aslan President and CEO, Director | Nov 17, 2025 | Sale(10b5-1 plan) | −6,375 | $3.38 | $21.55K | 343,999 |
| Fred Aslan President and CEO, Director | Nov 15, 2025 | Tax withholding | −6,347 | $3.25 | $20.63K | 350,374 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Aslan Fred Director, Officer | Oct 6, 2026 | 34,465 | $245.74K | Oct 6, 2026 | Restricted Stock Units |
| Aslan Fred Director, Officer | Sep 8, 2026 | 23,429 | $262.17K | Sep 8, 2026 | Restricted Stock Units |
| Banerjee Subhashis Officer | Aug 27, 2026 | 7,818 | $92.02K | Aug 27, 2026 | Exercise of Stock Options |
| Banerjee Subhashis Officer | Aug 18, 2026 | 833 | $9.78K | Aug 18, 2026 | Exercise of Stock Options |
| Fred Aslan, M.D. Officer, Director | May 18, 2026 | 28,000 | $258.16K | May 18, 2026 | Restricted Stock Units vesting under registered plan |
| Banerjee Subhashis Officer, Director | May 18, 2026 | 7,000 | $64.54K | May 18, 2026 | Restricted Stock Units vesting under registered plan |
| Bush Jennifer Officer, Director | May 18, 2026 | 9,000 | $82.98K | May 18, 2026 | Restricted Stock Units vesting under registered plan |
| P. Horan Christopher Officer, Director | May 18, 2026 | 7,500 | $69.15K | May 18, 2026 | Restricted Stock Units vesting under registered plan |
| Raymon Heather Officer, Director | May 18, 2026 | 3,500 | $32.27K | May 18, 2026 | Restricted Stock Units vesting under registered plan |
| Aslan Fred Director, Officer | Dec 15, 2025 | 12,749 | $42.07K | Dec 15, 2025 | Restricted Stock Units |
| Aslan Fred Director, Officer | Nov 17, 2025 | 6,375 | $20.72K | Nov 17, 2025 | Restricted Stock Units |
| Aslan Fred Director, Officer | Oct 17, 2025 | 25,500 | $70.64K | Oct 17, 2025 | Restricted Stock Units |
| Aslan Fred Director, Officer | Aug 15, 2025 | 25,500 | $68.85K | Aug 15, 2025 | Restricted Stock Units |